Company profile
BRAINSTORM CELL THERAPEUTICS INC. CIK 1137883
Ticker
BCLI (OTC)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
New York, NY 10019
Fiscal year end
2025 (FY)
Key Financials
Revenue
—
Net income
-$10.31M
Total assets
$1.02M
Total liabilities
$11.01M
Stockholders' equity
-$9.99M
Cash & equivalents
$29.0K
Operating income
-$9.95M
Operating cash flow
-$6.98M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-03-31. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
1,077.0%
Equity / assets
-977.0%
CapEx / revenue
—
Operating cash flow / net income
0.68×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
—
-$10.31M
$1.02M
$11.01M
-$9.99M
2024
—
-$11.62M
$1.83M
$9.60M
-$7.76M
2023
—
-$17.19M
$4.21M
$9.07M
-$4.86M
2022
—
-$24.28M
$8.45M
$11.47M
-$3.02M
2021
—
-$24.46M
$29.28M
$9.94M
$19.34M
Company Details
SIC code
2836
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-14
Financials filed via
Form 10-K
filed 2026-03-31
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
New York, NY 10019
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:42 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.